Tiffany Hall: Why Standard Pre-Op Labs Miss High-Risk Patients?
Tiffany Hall, Director of cPBM Clinical Technology at hc1, shared a post on LinkedIn:
“1 in 3 patients walks into elective surgery anemic – and current diagnostic thresholds may be hiding even more.
Melissa Hollo and Tiffany Hall analyzed pre-operative hemoglobin data from 50,033 patients across 40 U.S. hospitals (2021–2024) and found pre-operative anemia in 33.2% of them – with vascular surgery (52.4%) and women’s health surgery (45.7%) carrying the heaviest burden.
47% of those anemic patients were moderate-to-severe, the population most strongly linked to transfusion exposure and worse postoperative outcomes.
Even ‘mild’ anemia is an independent predictor of adverse events on its own, with risk climbing steadily with age (39.5% prevalence in patients over 65).
But here’s the missed opportunity underneath these numbers: we still diagnose anemia using sex-specific thresholds (Hb is low than 12 g/dL for women, is low than 13 g/dL for men) that don’t reflect actual physiologic oxygen delivery requirements during surgery.
Emerging evidence and international consensus recommendations now point to a uniform pre-operative threshold of is low than 13 g/dL for all patients, regardless of sex.
Applying the lower, sex-specific cutoff for women likely underestimates true anemia prevalence – meaning a meaningful share of at-risk women are being cleared for surgery who wouldn’t be under a physiologically grounded standard.
That’s the difference between a diagnostic threshold that was never built for the operating room and one that actually predicts surgical risk.
hc1 ClinicalIQ’s anemia management module closes that gap in-workflow – flagging at-risk patients from routine labs, surfacing the root cause, stratifying transfusion risk, and delivering evidence-based optimization recommendations before surgery day.
Analysis by Tiffany Hall and Melissa Hollo, hc1 Management Database (2021–2024, n=50,033, 40 U.S. hospitals).”

Stay updated with Hemostasis Today.
-
Oct 27, 2026, 11:43Tareq Abadl: Hidden Interferences Behind Unexpected Laboratory Results
-
Oct 27, 2026, 11:42Cece Calhoun: ASH Promotes Clinical Research Training and Mentorship for Emerging Hematologists
-
Oct 27, 2026, 11:41Ifeanyichukwu Ifechidere: The Laboratory Challenges of Measuring Direct Factor Xa Inhibitors
-
Oct 27, 2026, 11:39Gene Therapy Offers New Possibilities for Patients with Thalassaemia in the UAE – Thalassaemia International Federation
-
Oct 27, 2026, 11:35Alan Nurden: rFVIIa Prophylaxis May Reduce Bleeding-Related Healthcare Burden in Glanzmann Thrombasthenia
-
Oct 27, 2026, 10:12Cesar Garrido: WFH Connects with Spanish Thrombosis and Haematology Societies
-
Oct 27, 2026, 10:01Chokri Ben Lamine: CAPS After Autologous SCT – Diagnostic Criteria and Key Mimics
-
Oct 27, 2026, 09:45Jean Terrier: COBRRA Trial – Comparing Bleeding Risks Between DOACs
-
Oct 27, 2026, 08:42Kathleen Freson: SLFN14 at the Crossroads of RNA Regulation, Platelet Biogenesis and Inherited Thrombocytopenia